Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30026143 | 0.84 | CYP2A6 (0.70) | NPC1RAB9ATP53SMN1; SMN2CYP2A6 | |
| SCHEMBL20541087 | 0.84 | CYP2A6 (0.70) | NPC1RAB9ATP53SMN1; SMN2CYP2A6 | |
| SCHEMBL29412319 | 0.82 | MAPK14 (0.56) | NPC1RAB9ATP53SMN1; SMN2NPY5R | |
| SCHEMBL21489665 | 0.82 | NPC1 (0.51) | NPC1RAB9ATP53SMN1; SMN2NPY5R | |
| SCHEMBL12853987 | 0.82 | CYP2A6 (0.67) | TP53SMN1; SMN2CYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL21110859 | 0.82 | CYP2A6 (0.67) | TP53SMN1; SMN2CYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL27943394 | 0.82 | NPC1 (0.51) | NPC1RAB9ATP53SMN1; SMN2NPY5R | |
| SCHEMBL11068804 | 0.81 | NPC1 (0.50) | NPC1RAB9ATP53SMN1; SMN2NPY5R | |
| SCHEMBL16110614 | 0.81 | CYP17A1 (0.50) | NPC1RAB9ATP53SMN1; SMN2NPY5R | |
| SCHEMBL16513266 | 0.81 | NPY5R (0.67) | NPC1RAB9ATP53SMN1; SMN2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| WO-2019022435-A1 | COMPOUND FOR ORGANIC ELECTRONIC DEVICE, ORGANIC ELECTRONIC DEVICE USING SAME, AND ELECTRONIC APPARATUS THEREOF | 덕산네오룩스 주식회사 | 2019-01-31 | — | — | WO | disclosed |
| CN-108997342-A | A kind of two fluorene compound of more azaspiros and the organic electro-optic device containing the compound | 上海大学 | 2018-12-14 | — | — | CN | disclosed |
| EP-1572681-B1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-8110642-B2 | Synthesis of vinylphenylpyridine and living anionic polymerization | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-02-07 | — | — | US | disclosed |
| CN-1726209-B | 3-substituted-4-pyrimidone derivatives | SANOFI AVENTIS | 2011-04-13 | — | — | CN | disclosed |
| US-7683069-B2 | 3-substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20090105416-A1 | Synthesis of Vinylphenylpyridine and Living Anionic Polymerization | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-04-23 | — | — | US | disclosed |
| WO-2007129810-A1 | SYNTHESIS OF VINYLPHENYLPYRIDINE AND LIVING ANIONIC POLYMERIZATION | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-11-15 | — | — | WO | disclosed |
| US-20070142409-A1 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORPORATION OF OSAKA JAPAN | 2007-06-21 | — | — | US | disclosed |
| CN-1726209-A | 3-substituted-4-pyrimidone derivatives | SANOFI AVENTIS (JP) | 2006-01-25 | — | — | CN | disclosed |
| EP-1572681-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004055007-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | WO | disclosed |
| EP-1381606-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002074773-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| US-4244953-A | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines | AMERICAN CYANAMID COMPANY (US) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ACHE, TRPV1, OPRL1 | NPC1 2638/4885RAB9A 3565/4885TP53 4089/4885 |
| US-20090105416-A1 | Synthesis of Vinylphenylpyridine and Living Anionic Polymerization | PBRM1, MVD, PCBP1 | NPC1 4810/4885RAB9A 4209/4885TP53 2979/4885 |
| US-20070142409-A1 | 3-Substituted-4-pyrimidone derivatives | TTBK1, MAPT, TTBK2 | NPC1 2202/4885RAB9A 3514/4885TP53 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.